Skyline Therapeutics Receives FDA Clearance of IND for SKG0106, a Novel Intravitreally Delivered AAV Gene Therapy Candidate for Neovascular Age-related Macular Degeneration
On July 3, 2023, Skyline Therapeutics, an innovation-driven gene therapy company committed to developing unique and novel solutions for rare and severe diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for Phase I/IIa clinical trial of SKG0106. This is a one-time intravitreally delivered AAV gene therapy designed to treat neovascular age-related macular degeneration (nAMD). The global Phase I clinical trial will be initiated soon.
SKG0106 is a distinctively designed recombinant adeno-associated virus (rAAV)-mediated gene therapy specifically developed for ocular disease. It consists of a proprietary novel AAV caps